|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KCTD13 |
Gene summary for KCTD13 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KCTD13 | Gene ID | 253980 |
| Gene name | potassium channel tetramerization domain containing 13 | |
| Gene Alias | BACURD1 | |
| Cytomap | 16p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006260 | UniProtAcc | Q8WZ19 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 253980 | KCTD13 | LZE2T | Human | Esophagus | ESCC | 9.54e-06 | 3.86e-01 | 0.082 |
| 253980 | KCTD13 | LZE7T | Human | Esophagus | ESCC | 3.01e-10 | 4.47e-01 | 0.0667 |
| 253980 | KCTD13 | LZE22T | Human | Esophagus | ESCC | 1.57e-02 | 2.23e-01 | 0.068 |
| 253980 | KCTD13 | LZE24T | Human | Esophagus | ESCC | 5.01e-30 | 6.15e-01 | 0.0596 |
| 253980 | KCTD13 | LZE21T | Human | Esophagus | ESCC | 6.52e-03 | 1.77e-01 | 0.0655 |
| 253980 | KCTD13 | P1T-E | Human | Esophagus | ESCC | 2.65e-12 | 4.18e-01 | 0.0875 |
| 253980 | KCTD13 | P2T-E | Human | Esophagus | ESCC | 7.01e-38 | 6.31e-01 | 0.1177 |
| 253980 | KCTD13 | P4T-E | Human | Esophagus | ESCC | 3.85e-16 | 3.46e-01 | 0.1323 |
| 253980 | KCTD13 | P5T-E | Human | Esophagus | ESCC | 1.70e-10 | 1.40e-01 | 0.1327 |
| 253980 | KCTD13 | P8T-E | Human | Esophagus | ESCC | 1.42e-22 | 4.21e-01 | 0.0889 |
| 253980 | KCTD13 | P9T-E | Human | Esophagus | ESCC | 1.88e-05 | 1.27e-01 | 0.1131 |
| 253980 | KCTD13 | P10T-E | Human | Esophagus | ESCC | 2.11e-10 | 1.95e-01 | 0.116 |
| 253980 | KCTD13 | P11T-E | Human | Esophagus | ESCC | 2.10e-10 | 3.07e-01 | 0.1426 |
| 253980 | KCTD13 | P12T-E | Human | Esophagus | ESCC | 2.31e-18 | 2.97e-01 | 0.1122 |
| 253980 | KCTD13 | P15T-E | Human | Esophagus | ESCC | 1.19e-13 | 2.50e-01 | 0.1149 |
| 253980 | KCTD13 | P16T-E | Human | Esophagus | ESCC | 3.20e-13 | 2.27e-01 | 0.1153 |
| 253980 | KCTD13 | P17T-E | Human | Esophagus | ESCC | 4.79e-04 | 2.09e-01 | 0.1278 |
| 253980 | KCTD13 | P19T-E | Human | Esophagus | ESCC | 5.23e-14 | 4.89e-01 | 0.1662 |
| 253980 | KCTD13 | P20T-E | Human | Esophagus | ESCC | 2.96e-22 | 4.03e-01 | 0.1124 |
| 253980 | KCTD13 | P21T-E | Human | Esophagus | ESCC | 1.83e-11 | 2.18e-01 | 0.1617 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
| GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
| GO:00062604 | Esophagus | ESCC | DNA replication | 181/8552 | 260/18723 | 3.55e-15 | 2.05e-13 | 181 |
| GO:000701527 | Esophagus | ESCC | actin filament organization | 259/8552 | 442/18723 | 2.37e-08 | 4.50e-07 | 259 |
| GO:000726510 | Esophagus | ESCC | Ras protein signal transduction | 201/8552 | 337/18723 | 1.44e-07 | 2.30e-06 | 201 |
| GO:00062754 | Esophagus | ESCC | regulation of DNA replication | 73/8552 | 107/18723 | 1.97e-06 | 2.28e-05 | 73 |
| GO:005101727 | Esophagus | ESCC | actin filament bundle assembly | 100/8552 | 157/18723 | 3.87e-06 | 4.17e-05 | 100 |
| GO:006157227 | Esophagus | ESCC | actin filament bundle organization | 101/8552 | 161/18723 | 9.22e-06 | 8.82e-05 | 101 |
| GO:003003820 | Esophagus | ESCC | contractile actin filament bundle assembly | 67/8552 | 106/18723 | 2.03e-04 | 1.28e-03 | 67 |
| GO:004314920 | Esophagus | ESCC | stress fiber assembly | 67/8552 | 106/18723 | 2.03e-04 | 1.28e-03 | 67 |
| GO:000726610 | Esophagus | ESCC | Rho protein signal transduction | 81/8552 | 137/18723 | 1.03e-03 | 5.20e-03 | 81 |
| GO:00465789 | Esophagus | ESCC | regulation of Ras protein signal transduction | 106/8552 | 189/18723 | 2.49e-03 | 1.08e-02 | 106 |
| GO:00512592 | Esophagus | ESCC | protein complex oligomerization | 130/8552 | 238/18723 | 3.29e-03 | 1.36e-02 | 130 |
| GO:003103219 | Esophagus | ESCC | actomyosin structure organization | 108/8552 | 196/18723 | 4.86e-03 | 1.88e-02 | 108 |
| GO:00457406 | Esophagus | ESCC | positive regulation of DNA replication | 26/8552 | 40/18723 | 1.08e-02 | 3.66e-02 | 26 |
| GO:005105610 | Esophagus | ESCC | regulation of small GTPase mediated signal transduction | 157/8552 | 302/18723 | 1.55e-02 | 4.98e-02 | 157 |
| GO:001049822 | Liver | HCC | proteasomal protein catabolic process | 351/7958 | 490/18723 | 6.92e-40 | 1.46e-36 | 351 |
| GO:004316122 | Liver | HCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 299/7958 | 412/18723 | 7.82e-36 | 8.27e-33 | 299 |
| GO:000701522 | Liver | HCC | actin filament organization | 252/7958 | 442/18723 | 3.83e-10 | 1.25e-08 | 252 |
| GO:000726521 | Liver | HCC | Ras protein signal transduction | 187/7958 | 337/18723 | 8.89e-07 | 1.35e-05 | 187 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KCTD13 | insertion | Nonsense_Mutation | novel | c.353_354insCATTGTAGCTGGGAGTAGAATTGCTGGATAACAGGACACCTGCAAAC | p.Gly119IlefsTer10 | p.G119Ifs*10 | Q8WZ19 | protein_coding | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| KCTD13 | SNV | Missense_Mutation | novel | c.766N>A | p.Glu256Lys | p.E256K | Q8WZ19 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
| KCTD13 | SNV | Missense_Mutation | c.563N>T | p.Ser188Leu | p.S188L | Q8WZ19 | protein_coding | deleterious(0) | possibly_damaging(0.87) | TCGA-DS-A0VM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| KCTD13 | SNV | Missense_Mutation | novel | c.301N>T | p.Arg101Trp | p.R101W | Q8WZ19 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A9UL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
| KCTD13 | SNV | Missense_Mutation | c.475N>C | p.Glu159Gln | p.E159Q | Q8WZ19 | protein_coding | deleterious(0.03) | possibly_damaging(0.863) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| KCTD13 | SNV | Missense_Mutation | c.323N>T | p.Pro108Leu | p.P108L | Q8WZ19 | protein_coding | tolerated(0.07) | probably_damaging(0.97) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| KCTD13 | SNV | Missense_Mutation | novel | c.770N>T | p.Ala257Val | p.A257V | Q8WZ19 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| KCTD13 | SNV | Missense_Mutation | novel | c.589N>A | p.Glu197Lys | p.E197K | Q8WZ19 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| KCTD13 | deletion | Frame_Shift_Del | rs766440565 | c.421delN | p.Arg141GlyfsTer13 | p.R141Gfs*13 | Q8WZ19 | protein_coding | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| KCTD13 | SNV | Missense_Mutation | rs542780651 | c.332N>T | p.Thr111Met | p.T111M | Q8WZ19 | protein_coding | tolerated(0.06) | possibly_damaging(0.666) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |